StockIQ.techMerck & Co. Inc. (MRK) Stock Analysis
Free AI-powered analysis and research for Merck & Co. Inc. stock
Sector: Healthcare
MRK snapshot
Data as of 9 Oct 2026 close. Updated daily.
Merck & Co. Inc. scores 13/100 on StockIQ's model, which reads as strongly negative signals overall. The price is above its 200-day average and at 85% of its 52-week range, up 69.3% over the past year. Latest reported figures show a profit margin of 4.8%, return on equity of 7.0% and revenue growth of +5.1%.
What is driving the score
- RSI Neutral: +5
- Below 20-day MA: -6
- MACD Bearish: -8
- High P/E (110.7): -10
- Weak Profit Margin (4.8%): -8
- Weak Liquidity (1.32 Current Ratio): -5
- High P/B (8.21): -5
- Strong Long-term Uptrend: +8
- Overextended (+69.3% over 1 year): -8
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full MRK report
Merck & Co. Inc. (MRK) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze MRK Now →📰 Latest Update
Jefferies cuts Merck’s remigromig sales forecast after eye-disease trial raises concerns
Mon, October 12, 2026 at 3:12 PM UTC 4 min read
Jefferies has downgraded its sales forecast for Merck's remigromig following concerns raised by a recent eye-disease trial. This adjustment reflects potential challenges in the drug's market performance, which could impact Merck's revenue projections and overall growth strategy. Investors should monitor these developments closely, as they may influence the company's stock performance and future earnings outlook.